GRISEOFULVIN (griseofulvin (microsize)) by Molecular Devices is clinical pharmacology griseofulvin oral suspension, usp acts systemically to inhibit the growth of trichophyton, microsporum, and epidermophyton genera of fungi. First approved in 2005.
Drug data last refreshed 19h ago
Clinical Pharmacology Griseofulvin Oral Suspension, USP acts systemically to inhibit the growth of Trichophyton, Microsporum, and Epidermophyton genera of fungi. Fungistatic amounts are deposited in the keratin, which is gradually exfoliated and replaced by noninfected tissue. Griseofulvin…
Tubulin Inhibiting Agent
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Bioequivalence (BE) Study of Test Griseofulvin 500 Milligram (mg) Tablets Versus Reference and Dose Proportionality Study of Test Griseofulvin 250 mg and 500 mg Tablets Under Fed Conditions
Terbinafine Compared to Griseofulvin in Children With Tinea Capitis
Terbinafine Compared to Griseofulvin in Children With Tinea Capitis
Worked on GRISEOFULVIN at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.